Intracranial Meningeal Enhancement Characterization
Rev Colomb Radiol 28:4709-4716, Mera, J.L.C.,et al, 2017
Neuroimaging Findings in Children and Young Adults with Neurotoxicity after CAR T-Cell Therapy for B-Cell Malignancies
Neurol 105:e214086, McGuire,J.L.,et al, 2025
Cytotoxic Lesions of the Corpus Callosum That Show Restricted Diffusion: Mechanisms, Causes, and Manifestations
RadioGraphics 37:562-576, Starkey, J.,et al, 2017
Clinical Reasoning: A 28-year-old IV Drug User with Bilateral Basal Ganglia and Brainstem Lesions
Neurol 80:e73-e76, Lin, T.,et al, 2013
Movement Disorders Emergencies Part 1
, Robottom, B.J., et al, 2011
Clomipramine Induced Neuroleptic Malignant Syndrome and Pyrexia of Unknown Origin
BMJ 329:1333-1335, Haddow,A.M.,et al, 2004
Acute, Drug-Induced, Life-Threatening Neurological Syndromes
The Neurologist 4:196-210, Richard,I.H., 1998
Neurotoxicity After Treatment with Muromonab-CD3
NEJM 323:487-488, Richards,J.M.,et al, 1990
Neuroleptic Malignant Syndrome, Review of Response to Therapy
Arch Int Med 149:1927-1931, Rosenberg,M.R.&Green,M., 1989
Eosinophilia-Myalgia Syndrome-New Mexico
JAMA 262:3116, Belvins,W.L.,et al, 1989
Neuroleptic Malignant Syndrome
Arch Neurol 37:462-463, Morris,H.H.,et al, 1980
Anticholinergics
NEJM 288:1215, Greenblatt,D.J.,et al, 1973
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Drug Reaction with Eosinophilia and Systemic Symptoms after Daclizamub Therapy
Neurol 91:e359-e363, Rauer,S.,et al, 2018
Spectrum of Neurologic Complications in Chronic Lymphocytic Leukemia
Clin Lymphoma Myeloma Leuk 12:164-179, Lopes da Silva, R., 2012
Reversible Cerebral Vasoconstruction Syndromes
Arch Neurol 68:1005-1012,976, Singhal, A.B.,et al, 2011
Delayed Leukoencephalopathy with Stroke-Like Presentation in Chemotherapy Recipients
JNNP 79:535-539, Baehring,J.M. &Fulbright,R.K., 2008
Risk Factors of Cerebral Vein and Sinus Thrombosis
Front Neurol Neurosci 23:23-54, de Freitas, G.R. & Bogousslavsky, J., 2008
Statin-Associated Myasthenia Gravis
Medicine 85:82-85, Purvin,V.,et al, 2006
Cerebral Sinus Thrombosis with Tamoxifen
Neurol 56:1113-1114, Finelli,P.F. & Schauer,P.K., 2001
Drugs and Myasthenia Gravis, An Update
Arch Int Med 157:399-408, Wittbrodt,E.T., 1997
Opsoclonus
Semin Neurol 16:21-26, Averbuch-Heller,L.&Remler,B., 1996
Nocturnal Blood Pressure Dip in Stroke Survivors, A Pilot Study
Stroke 26:1373-1378, Nakamura,K.,et al, 1995
Reversible Neurologic Toxicity with Fludarabine Phosphate for Mycosis Fungiodes & Chronic Lymphocytic Leukemia
Ann Int Med 118:114-116, Cohen,R.B.,et al, 1993
Phenobarbital Rheumatism in Patients with Brain Tumor
Ann Neurol 25:92-94, Taylor,L.P.&Posner,J.B., 1989
Azathioprine Toxicity During Long-Term Immunosuppression of Generalized Myasthenia Gravis
Neurol 38:258-261, Hohlfeld,R.,et al, 1988
Opsoclonus in Adults
Arch Neurol 43:1165-1175, Digre,K.B., 1986
Hypoglycemia:Fact or Fiction
Mayo Clin Proc 60:844-850, Nelson,R.L., 1985
The Neurotoxicity of Antibacterial Agents
Ann Int Med 101:92-104, Snavely,S.R.,et al, 1984
Beta-Adrenoreceptor Antagonists & Diplopia
Lancet 2:826-827, Weber,J.C.P., 1982
Disorders of Neuromuscular Transmission Caused by Drugs
NEJM 301:409-413, Argov,Z.,et al, 1979